The present invention is concerned with compounds of formula
##STR1##
the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically
isomeric forms thereof, wherein X represents O, S or NR3; R1 represents
hydrogen, hydroxy, C1-6alkyl or aryl; R2 represents hydrogen;
optionally substituted C1-12alkyl; C3-7cycloalkyl; C2-8alkenyl;
aryl; Het1; or R1 and R2 taken together may form
a bivalent radical of formula -(CH2)n- wherein n is 2, 3,
4, 5 or 6; R3 represents hydrogen, optionally substituted C1-6alkyl,
aryl, Het1; R4 represents hydrogen; hydroxy; mercapto; C1-6alkyloxy;
C1-6alkylthio; aryloxy; arylthio; Het1-oxy; Het1-thio;
optionally substituted C1-12alkyl; optionally substituted C2-8alkenyl;
optionally substituted C2-8alkynyl; optionally substituted C3-7cycloalkyl;
optionally substituted C5-7cycloalkenyl; aryl; Het1; or -Alk-NR3R5
(i) or -NR3R5 (ii) wherein Alk represents C1-6alkanediyl;
and R5 represents hydrogen, C1-6alkyl, aryl, Het1,
(aryl or Het1)C1-6alkyl, (aryl or Het1)carbonyl
or (aryl or Het1)C1-6alkyloxycarbonyl; aryl represents optionally
substituted indanyl, indenyl, naphtyl, 5,6,7,8-tetrahydro-2-naphtalenyl or phenyl;
Het represents an optionally substituted unsaturated heterocycle; and Het1
represents an optionally substituted monocyclic or bicyclic heterocycle;
having retinoic mimetic activity; their preparation, compositions containing them
and their use as a medicine.
